HeartSciences (NASDAQ:HSCS) CEO Andrew Simpson joined Steve Darling from Proactive to share details about the company that bring innovative AI-based technology to an ECG to expand and improve an ECG’s clinical usefulness. Simpson shares with Proactive more about how they do that using its first product candidate for FDA clearance, the MyoVista wavECG. This product, according to the company, is a resting 12-lead ECG that is also designed to provide more diagnostic information which has traditionally only been available through the use of cardiac imaging.
HeartSciences using technology to help make lifesaving ECG’s better using Artificial Intelligence
